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Diabetes, rare in the neonatal period, should be evoked in every newborn presenting 
with unexplained intrauterine and early postnatal growth retardation. This case report 
illustrates the clinical course and therapeutic approach of a newborn diagnosed with 
transient diabetes. The baby was born at 37 weeks of gestation with a severe intrauterine 
growth restriction. Except a mild macroglossia and signs of growth restriction, physical 
examination was normal. On the fifth day of life, hyperglycemia (180 mg/dl) was noted, 
and the next day, the diagnosis of diabetes was confirmed (high blood sugar, glucosuria, 
undetectable levels of insulin and C-peptide). Insulin infusion, initially intravenously and 
then subcutaneously, was started, tailored to assure the growth catch-up and normalize 
the blood sugar levels. At the age of 4 weeks, the baby returned at home under pump. 
At 8  weeks, the clinical impression of evolution to a transient diabetes (decreasing 
needs of insulin with very satisfactory weight gain) was genetically confirmed (paternal 
uniparental disomy of chromosome 6). There is no screening for neonatal diabetes, but 
the clinical suspicion avoids the metabolic decompensation and allows early initiation of 
insulin therapy. The genetic approach (for disease itself and its associated features) relies 
on timely clinical updates.
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INtRoDUCtIoN
Neonatal diabetes is a differential diagnosis to be evoked in newborns at term with intrauterine growth 
restriction (IUGR) and early unsatisfactory postnatal weight evolution. Its genetic characterization 
can be available in 1–2 weeks and guides the therapeutic approach. Two subgroups are defined today 
on clinical and genetic background: transient and permanent neonatal diabetes mellitus.
Approximately 50% of the neonatal diabetes cases require lifelong treatment to control glycemia 
(permanent diabetes), and for the remaining half of the cases, a spontaneous remission is observed, 
usually within the first 3 months (transient diabetes), and a clinical relapse is always possible (1).
Early diagnosis based on the clinical and biological background avoids the metabolic catastrophe 
of ketoacidosis and allows early insulin therapy initiation. There are no guidelines for diabetes man-
agement during the first months of life, but two remarks are of unquestionable value – these babies 
need insulin with adequate or high caloric intake to assure a satisfactory weigh gain and, in the era 
of advanced technology, insulin administration could partially mimic the pancreas physiology. The 
availability of genetic results (in a couple of weeks) definitively changed the short- and long-term 
management of these babies.
FIGURe 2 | Glycemic variations during intravenous insulin therapy.
FIGURe 1 | Insulin requirement evolution.
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We present a case of transient neonatal diabetes (complete 
loss of methylation on chromosome 6q24) managed mostly by 
continuous subcutaneous insulin infusion (CSII), with very short 
hospital stay (3 weeks). The immediate and at distance evolution 
was favorable, with complete restoration of anthropometric 
parameters at the age of 3 months and no hyper- or hypoglycemic 
events.
Case RepoRt
A 5-day-old newborn boy was transferred to our Neonatal 
Intensive Care Unit for unfavorable postnatal growth progression, 
in absence of any symptoms. He was born at 37 weeks of gestation 
and presented a severe IUGR with birth weight 1980 g (<3rd per-
centile), length 43 cm (<3rd percentile), and head circumference 
30  cm (<3rd percentile on WHO chart). His both parents are 
healthy, and the overall medical family history is irrelevant. On 
physical examination, he was well-appearing, with normal vital 
signs and normal hydration status, but the subcutaneous tissue 
was underdeveloped. There were no dysmorphic features, unless 
a mild macroglossia. Neurologically, the baby was relatively well, 
but a certain hypotonia was noted. He was breastfed with normal 
suction reflex but poor weight gain.
During the first days of life, routine blood sugar monitoring 
performed for newborn with IUGR was normal. Laboratory 
investigations did not find any explanation for the severe IUGR.
On the fifth day, the capillary blood sugar was at 180 mg/dl, 
with no concomitant glucosuria, in the absence of any stress. The 
venous blood sugar collected the next day went up to 300 mg/dl, 
with glucosuria and the extensive glucose metabolism evaluation 
confirmed the diagnosis of neonatal diabetes – high blood sugar 
(400 mg/dl) with glucosuria but no ketonuria and undetectable 
levels of insulin (1.4–1.6 mUI/l) and C peptide (0.14–0.16 nmol/l).
The insulin infusion was started (insulin diluted in a 1:100 
mixture with normal saline), initially intravenously, trying to 
attain euglycemia and to get a positive growth evolution with 
consequent development of subcutaneous tissue. The insulin 
infusion rates were regularly titrated according to preprandial 
blood sugar levels, type of milk (breast or enriched formula), and 
postprandial (60 min) glycemia.
His initial insulin needs at 2.2 U/kg/day were relatively higher 
than those described in the literature, but the baby started to gain 
weight, between 30 and 50 g daily, and developed more subcuta-
neous tissue, mostly on thighs. Neurologically, he became more 
active.
At the age of 17 days (11 days after diagnosis), when the sub-
cutaneous tissue allowed us to adequately insert a catheter, the 
intravenous insulin infusion was switched to subcutaneous one 
(CSII), with no technical and skin problems in the evolution. The 
baby continued to improve his nutritional status (median daily 
weight gain of 30 g) and got more and more glycemic stability 
while reducing insulin requirements (Figure 1).
The insulin infusion was definitively stopped at the age of 
8  weeks, when the amount was 0.2  U/kg/day and preprandial 
blood glucose levels between 60 and 70 mg/dl.
Almost 40% of total daily insulin dose was infused con-
tinuously as basal rate and the remaining 60% as mealtime 
boluses. Two different basal rates were set, one between the 
meals (0.05 U/h) and the second one during 1 h after each meal 
(0.07 U/h). Initially, the boluses were administered before each 
meal, but progressively, less frequent boluses were required 
(bolus if premeal blood sugar higher than 200  mg/dl). The 
amount of insulin infused as bolus was calculated using the 
insulin sensitivity (0.1 U to lower blood glucose by 40 mg/dl), 
and some adaptations were made depending on type of milk 
(human or enriched formula). At home, the basal rate was set at 
0.06 U/h, and the boluses were infused if preprandial glycemia 
was above 150 mg/dl.
The blood glucose target was initially set between 100 and 
250 mg/dl, trying to avoid the hypoglycemia-induced brain dam-
age, particularly in newborn receiving exogenous insulin.
Of course, we noted some glycemic excursions during the first 
days of intravenous insulin therapy (Figure  2), but after then, 
blood glucose variability decreased significantly, with almost all 
readings within the target range (100–250 mg/dl) (Figure 3). We 
changed progressively the target range, with a less wide target at 
the age of 4 weeks (at discharge) – 100–200 mg/dl.
taBLe 1 | Newborn data summary.
Birth parameters Ga (weeks) Weight (g/percentiles) Height (cm/percentiles)
37 1980 (<3rd P) 43 cm (<3rd P)
Diagnosis Age Weight Biological parameters
6 days 1890 g Glycemia 400 mg/dl
Glucosuria++
No ketonuria
Insulin 1.4–1.6 mUI/l (2–17)
C peptide 0.14–0.16 nmol/l (0.37–1.47)
Insulin therapy Intravenous CSII Age of discontinuation
From 6 to 17 days of life (total of 11 days) From 17 days to 8 weeks of life 8 weeks
Genetic diagnosis PND excluded (no INS, KCNJ11 and ABCC8 
gene pathogenic mutations)
TND confirmed (complete loss of methylation on 
chromosome 6q24 – paternal uniparental isodisomy)
Age of 6 weeks Age of 8 weeks
Clinical follow-up 
(months)
3 6 9
Weight 5400 g (15th P) Weight 6820 g (3rd–15th P) Weight 8000 g (15th P)
Length 58 cm (15th P) Length 64 cm (15th P) Length 69 cm (15th P)
Head circumference 36 cm Head circumference 42 cm Head circumference 44.5 cm (15th P)
P, percentile; CSII, continuous subcutaneous insulin infusion; PND, permanent neonatal diabetes; TND, transient neonatal diabetes; INS, insulin.
FIGURe 3 | Glycemic variations on CsII (the first 3 weeks).
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There were no hypoglycemic accidents in his evolution. The 
use of continuous glucose monitoring (CGM) system was techni-
cally difficult; so the glycemic monitoring was mostly made by 
capillary sampling.
During the first 2 weeks, the baby was breastfed during the 
day, and during the night, he received 60  ml of enriched milk 
formula every 3 h (to prevent nocturnal hypoglycemia and assure 
a relatively higher-caloric intake recommended in newborn with 
IUGR). After 2 weeks, he was exclusively breastfed, with favorable 
weight gain.
The clinical suspicion of transient diabetes was more frequently 
evoked notably when, at the age of 4 weeks, the genetic results for 
permanent neonatal diabetes did not identify any mutation in 
INS, KCNJ11, and ABCC8 genes. From the fifth to eighth weeks 
of life, the infant presented a favorable catch up growth associated 
with a progressive decline of insulin infusion and stable metabolic 
profile. The clinical impression of evolution to a transient diabetes 
(decreasing needs of insulin with definitive stop at the age of 
8  weeks) was soon confirmed by genetic testing performed at 
the Institute of Biomedical and Clinical Research, University of 
Exeter Medical School, showing a complete loss of methylation 
on chromosome 6q24 (paternal uniparental isodisomy).
A regular clinical follow-up was set up. At the age of 9 months, 
the baby develops very well, with normal anthropometric param-
eters, no infectious episodes and no hyper- or hypoglycemic 
events. The parents were informed about the necessity of long-
term follow-up because the risk of recurrence is not insignificant 
and there are no clinical, biological, or genetic correlations to 
predict a possible recurrence.
The most important baby’s characteristics are briefly depicted 
in Table 1.
DIsCUssIoN
Clinical and molecular insight into neonatal diabetes has greatly 
advanced, and nowadays, we describe it as a monogenic disease 
and relationship between genotype and phenotype emerges.
On the clinical ground, it is very difficult to clearly differentiate 
the two types of neonatal diabetes. There is also a great genetic 
heterogeneity associated with neonatal diabetes, and important 
advances are currently made in defining some phenotype– 
genotype correlations.
For the transient neonatal diabetes, as genetic form of pan-
creatic β-cell dysfunction, two distinctive genotype–phenotype 
associations are defined. The 70% of cases are secondary to 
methylation abnormalities at chromosome 6q24 (paternal unipa-
rental disomy, paternal duplication, loss of methylation without a 
structural defect), present with moderate-to-severe intrauterine 
growth retardation and develop early (during the first week of 
life) isolated moderate non-ketotic hyperglycemia. Despite this 
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initial severe clinical appearance, the remission is evident before 
the age of 3  months and later relapse is possible. Few cases of 
transient diabetes are associated with functional abnormalities 
of KATP channels on the β-cell membrane (activating mutations 
of KCNJ11 and ABCC8 genes), and some clinical particularities 
could be retained, as higher weight at birth, later onset of hyper-
glycemia, and relatively retarded remission (2).
New genetic subtypes, including some pancreatic develop-
ment transcriptions factors (GATA6, PAX6, NEUROG3, and 
NEUROD1), were recently described, particularly those linked to 
a phenotypic spectrum comprising diabetes and extrapancreatic 
features (3).
Today, even if the molecular diagnosis in babies with neonatal 
diabetes is quickly available and allows a better therapeutic and 
prognosis delineation, the initial clinical presentation (with all 
clinical and biological details) remains helpful for initial gene-
candidate selection through molecular analysis.
In our case, we had all the clinical criteria to argue for tran-
sient diabetes: weight at birth, age when first hyperglycemia was 
detected, mild macroglossia and no other particular features, 
normal neurological status, relatively high starting doses of 
insulin with progressive diminution, and definitive stop before 
the age of 3 months. Additionally, at the age of 4 weeks, the first 
genetic result excluded the most frequent mutations associated 
with permanent diabetes. The genetic confirmatory results were 
available at the age of 8 weeks, and at this age, we have already 
stopped the insulin therapy.
While waiting for the genetic results, the medical treatment 
is the same and must target first an appropriate caloric intake to 
improve the nutritional status of these babies and insulin admin-
istration for an adequate blood sugar control (4, 5). Insulin is 
absolutely required and should be started as soon as the diagnosis 
was made. The way of administration and the amount required 
can vary depending on some clinical and technical aspects. All 
these babies had suffered a certain growth restriction, so their 
subcutaneous tissue is not adequately developed at birth and 
insulin absorption can be excessively erratic. In such conditions, 
intravenous insulin infusion could be the most practical option 
for initiating the insulin therapy. We started by intravenous 
access, with the continuous infusion rate and the preprandial 
boluses calculated depending on the premeal blood sugar level, 
milk formula type, and postprandial glycemia, trying to mini-
mize the risk of hypoglycemia and glycemic variations. Eleven 
days later, after obtaining a stable glucose level and having more 
subcutaneous tissue available, we installed the pump and the baby 
returned at home at the age of 4 weeks. We appreciate the CSII 
could be an accurate, almost physiologic method to infuse insulin 
in newborns, and its major benefit was the ability to follow, flex-
ibly, the baby’s blood glucose fluctuations.
In conclusion, neonatal diabetes is still a challenging entity, 
clinically, therapeutically, and genetically. From a clinical point 
of view, early diagnosis and medical management (continuous 
insulin infusion and high caloric intake) are required to avoid 
serious metabolic complications and allow adequate weight 
gain and neurological development in these moderate-to-severe 
growth-restricted babies. Clinical, biological, and evolution char-
acteristics are useful tools in defining the molecular diagnosis. For 
babies with transient diabetes, regular follow-up, particularly in 
the first years of life is highly recommended because symptomatic 
hypoglycemia or recurrent hyperglycemia can be present during 
banal infections events (6).
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